Chidozie Ugwumba Sells 3,800 Shares of Clene (NASDAQ:CLNN) Stock

Posted by Bonnie Powley on Feb 2nd, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 3,800 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $4.04, for a total value of $15,352.00. Following the sale, the insider owned 555,559 shares in the company, valued at approximately $2,244,458.36. The trade was a 0.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The shares were sold at an average price of $4.13, for a total transaction of $23,483.18.
On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total transaction of $66,026.88.
On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The shares were sold at an average price of $4.91, for a total transaction of $42,800.47.
On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The shares were sold at an average price of $5.08, for a total value of $21,026.12.
On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total value of $32,218.36.
On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The shares were sold at an average price of $5.27, for a total value of $29,280.12.
On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total transaction of $67,377.80.
On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The stock was sold at an average price of $5.05, for a total transaction of $61,200.95.
On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60.
On Friday, January 16th, Chidozie Ugwumba sold 7,923 shares of Clene stock. The stock was sold at an average price of $5.13, for a total transaction of $40,644.99.

Clene Stock Performance

Shares of CLNN stock traded down $0.05 during trading hours on Monday, hitting $4.04. 61,269 shares of the company were exchanged, compared to its average volume of 123,008. The stock has a market capitalization of $43.83 million, a price-to-earnings ratio of -1.19 and a beta of 0.82. Clene Inc. has a one year low of $2.28 and a one year high of $13.50. The business’s 50-day simple moving average is $6.34 and its two-hundred day simple moving average is $6.56.

Clene (NASDAQ:CLNN – Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. As a group, analysts anticipate that Clene Inc. will post -5.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Clene

Institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp bought a new position in Clene during the 3rd quarter valued at $29,000. Jane Street Group LLC purchased a new position in Clene in the 2nd quarter worth about $47,000. Lunt Capital Management Inc. increased its stake in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after purchasing an additional 21,217 shares in the last quarter. Finally, Scoggin Management LP raised its holdings in Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after buying an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on CLNN. UBS Group restated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research note on Friday, January 9th. Benchmark restated a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of Clene in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.60.

View Our Latest Research Report on Clene

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).